Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 17, 2019 - Issue 4
Submit an article Journal homepage
10,596
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Should all diabetic patients take statin therapy regardless of serum cholesterol level?

Salam KhalilDetroit Medical Center, Detroit Heart Hospital, Wayne State University, Detroit, MI, USAView further author information
,
Sinan KhayyatDetroit Medical Center, Detroit Heart Hospital, Wayne State University, Detroit, MI, USAView further author information
,
Yasser Al-KhadraDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, USAView further author information
&
M. Chadi AlraiesDetroit Medical Center, Detroit Heart Hospital, Wayne State University, Detroit, MI, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-7874-4566View further author information
ORCID Icon
Pages 237-239 | Received 14 Sep 2018, Accepted 28 Feb 2019, Published online: 11 Mar 2019

References

  • Statistics AD. ADA diabetes statistics. 2018 [cited 2018 May 09]. Available from: http://www.diabetes.org/diabetes-basics/statistics/
  • Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5(3):150.
  • Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985;110(5):1100–1107.
  • Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496–1504.
  • Hamilton SJ, Watts GFJ, TrodsR. Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud. 2013;10(2–3):133.
  • ASCVD. 2108 [cited 2018 May 09]. Available from: http://www.cvriskcalculator.com/
  • care ADAJD. 9. Cardiovascular disease and risk management: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S86–S104.
  • Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696.
  • Taylor F, Huffman MDMacedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816. doi: 10.1002/14651858.CD004816.
  • Trialists CTJTL. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125.
  • Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(s2):1–87.
  • Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–2016.
  • Meek C, Wierzbicki AS, Jewkes C, et al. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin. 2012;28(3):371–378.
  • Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291(23):2821–2827.
  • Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with vs. without diabetes: results from improve-IT. Circulationaha. 2017;117:030950.
  • Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8(6):554–561.
  • Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate+ statin versus gemfibrozil+ any statin. Am J Cardiol. 2005;95(1):120–122.
  • Medicine A-HIJNEJo. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.